Sophia Genetics Sa Financials

SOPH

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Sophia Genetics Sa (SOPH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 39/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Growth

Sophia Genetics Sa's revenue surged 18.6% year-over-year to $77.3M, reflecting rapid business expansion. This strong growth earns a score of 64/100.

Leverage

Sophia Genetics Sa carries a low D/E ratio of 0.27, meaning only $0.27 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Sophia Genetics Sa's current ratio of 1.96 indicates adequate short-term liquidity, earning a score of 35/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While Sophia Genetics Sa generated -$35.9M in operating cash flow, capex of $574K consumed most of it, leaving -$36.5M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Sophia Genetics Sa generates a -167.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -64.8% the prior year.

Piotroski F-Score Weak

3/9

Sophia Genetics Sa passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.45x

For every $1 of reported earnings, Sophia Genetics Sa generates $0.45 in operating cash flow (-$35.9M OCF vs -$79.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$77.3M

YoY+18.6%

5Y CAGR+22.2%

Sophia Genetics Sa generated $77.3M in revenue in fiscal year 2025. This represents an increase of 18.6% from the prior year.

EBITDA

N/A

Net Income

-$79.0M

YoY-26.4%

Sophia Genetics Sa reported -$79.0M in net income in fiscal year 2025. This represents a decrease of 26.4% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

-$36.5M

YoY+18.5%

Sophia Genetics Sa generated -$36.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 18.5% from the prior year.

Cash & Debt

$70.3M

YoY-12.4%

5Y CAGR-1.2%

Sophia Genetics Sa held $70.3M in cash against $12.6M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

68M

YoY+2.7%

Sophia Genetics Sa had 68M shares outstanding in fiscal year 2025. This represents an increase of 2.7% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

-102.2%

YoY-6.3pp

5Y CAGR+36.3pp

Sophia Genetics Sa's net profit margin was -102.2% in fiscal year 2025, showing the share of revenue converted to profit. This is down 6.3 percentage points from the prior year.

Return on Equity

-167.6%

YoY-102.8pp

5Y CAGR-128.4pp

Sophia Genetics Sa's ROE was -167.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 102.8 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$574K

YoY+135.2%

5Y CAGR+5.0%

Sophia Genetics Sa invested $574K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 135.2% from the prior year.

SOPH Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$77.3M+18.6%	$65.2M+4.5%	$62.4M+31.1%	$47.6M+17.6%	$40.5M+42.4%	$28.4M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$573K+1.1%	$567K+4.0%	$545K+29.1%	$422K+87.6%	$225K+86.0%	$121K
Income Tax	$1.5M+23.6%	$1.2M+151.6%	$486K+457.4%	-$136K-181.0%	$168K+108.9%	-$1.9M
Net Income	-$79.0M-26.4%	-$62.5M+20.9%	-$79.0M+9.7%	-$87.4M-18.7%	-$73.7M-87.3%	-$39.3M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Revenue	N/A	$18.3M	N/A	$15.8M	N/A	$15.1M	N/A	$11.7M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	-$1.3M	N/A	-$608K
Income Tax	N/A	$762K	N/A	$161K	N/A	$73K	N/A	-$6K
Net Income	N/A	-$22.4M	N/A	-$15.2M	N/A	-$21.4M	N/A	-$24.7M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SOPH Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$163.0M+5.0%	$155.3M-24.7%	$206.2M-15.5%	$243.8M-23.8%	$320.2M+142.3%	$132.1M
Current Assets	$99.1M-0.3%	$99.4M-32.9%	$148.0M-24.6%	$196.3M-30.6%	$282.9M+157.9%	$109.7M
Cash & Equivalents	$70.3M-12.4%	$80.2M-34.9%	$123.3M-23.6%	$161.3M-16.4%	$193.0M+158.6%	$74.6M
Inventory	$6.4M+8.2%	$5.9M-9.5%	$6.5M+25.7%	$5.2M-10.0%	$5.7M+69.3%	$3.4M
Accounts Receivable	$15.0M+101.7%	$7.4M-45.2%	$13.6M+103.9%	$6.6M+5.9%	$6.3M-1.3%	$6.4M
Goodwill	$35.9M+23.8%	$29.0M+6.7%	$27.2M+36.2%	$20.0M+27.4%	$15.7M+18.0%	$13.3M
Total Liabilities	$115.9M+97.0%	$58.8M+7.5%	$54.7M+25.2%	$43.7M-2.4%	$44.8M+41.7%	$31.6M
Current Liabilities	$50.5M+88.5%	$26.8M-24.8%	$35.6M+32.9%	$26.8M-6.3%	$28.6M+32.5%	$21.6M
Long-Term Debt	$12.6M-13.8%	$14.6M-6.8%	$15.7M+11.5%	$14.1M+25.0%	$11.2M+290.1%	$2.9M
Total Equity	$47.1M-51.1%	$96.5M-36.3%	$151.4M-24.3%	$200.1M-27.3%	$275.4M+174.0%	$100.5M
Retained Earnings	-$519.3M-17.9%	-$440.3M-16.5%	-$377.8M-26.4%	-$298.8M-41.4%	-$211.4M-53.5%	-$137.7M

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Total Assets	$163.0M-8.2%	$177.6M+14.4%	$155.3M-14.2%	$181.1M-12.2%	$206.2M-7.6%	$223.2M-8.5%	$243.8M	N/A
Current Assets	$99.1M-15.3%	$117.0M+17.7%	$99.4M-21.0%	$125.8M-15.1%	$148.0M-12.2%	$168.6M-14.1%	$196.3M	N/A
Cash & Equivalents	$70.3M-25.9%	$94.8M+18.2%	$80.2M-23.9%	$105.4M-14.5%	$123.3M-17.0%	$148.6M-7.9%	$161.3M-9.8%	$178.9M
Inventory	$6.4M+2.2%	$6.2M+5.9%	$5.9M-10.3%	$6.5M+1.0%	$6.5M+18.8%	$5.5M+5.9%	$5.2M	N/A
Accounts Receivable	$15.0M+57.8%	$9.5M+27.8%	$7.4M-25.1%	$9.9M-26.8%	$13.6M+37.7%	$9.8M+48.1%	$6.6M	N/A
Goodwill	$35.9M	N/A	$29.0M	N/A	$27.2M	N/A	$20.0M	N/A
Total Liabilities	$115.9M+14.8%	$100.9M+71.6%	$58.8M-1.4%	$59.7M+9.0%	$54.7M+6.2%	$51.5M+17.8%	$43.7M	N/A
Current Liabilities	$50.5M+46.5%	$34.5M+28.7%	$26.8M-6.3%	$28.6M-19.7%	$35.6M+12.9%	$31.5M+17.7%	$26.8M	N/A
Long-Term Debt	$12.6M-9.2%	$13.9M-5.1%	$14.6M+3.2%	$14.2M-9.7%	$15.7M-4.2%	$16.4M+16.4%	$14.1M	N/A
Total Equity	$47.1M-38.5%	$76.7M-20.5%	$96.5M-20.5%	$121.4M-19.8%	$151.4M-11.8%	$171.7M-14.2%	$200.1M-12.3%	$228.1M
Retained Earnings	-$519.3M-8.2%	-$480.1M-9.0%	-$440.3M-8.3%	-$406.7M-7.6%	-$377.8M-11.1%	-$339.9M-13.8%	-$298.8M	N/A

SOPH Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$35.9M+19.4%	-$44.5M+16.4%	-$53.2M+24.1%	-$70.1M-21.0%	-$57.9M-82.6%	-$31.7M
Capital Expenditures	$574K+135.2%	$244K-83.7%	$1.5M-63.5%	$4.1M+52.7%	$2.7M+496.2%	$450K
Free Cash Flow	-$36.5M+18.5%	-$44.8M+18.2%	-$54.7M+26.2%	-$74.2M-22.4%	-$60.6M-88.4%	-$32.2M
Investing Cash Flow	-$8.7M-82.3%	-$4.8M-136.6%	$13.0M-69.1%	$42.0M+173.7%	-$56.9M-134.1%	-$24.3M
Financing Cash Flow	$30.2M+206.1%	$9.9M+449.2%	-$2.8M-80.0%	-$1.6M-100.7%	$237.8M+122.1%	$107.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SOPH Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-102.2%-6.3pp	-95.9%+30.7pp	-126.6%+57.2pp	-183.9%-1.7pp	-182.1%-43.6pp	-138.5%
Return on Equity	-167.6%-102.8pp	-64.8%-12.6pp	-52.1%-8.4pp	-43.7%-16.9pp	-26.8%+12.4pp	-39.1%
Return on Assets	-48.5%-8.2pp	-40.2%-1.9pp	-38.3%-2.5pp	-35.9%-12.8pp	-23.0%+6.8pp	-29.8%
Current Ratio	1.96-1.7	3.71-0.4	4.16-3.2	7.32-2.6	9.89+4.8	5.08
Debt-to-Equity	0.27+0.1	0.15+0.0	0.10+0.0	0.07+0.0	0.04+0.0	0.03
FCF Margin	-47.2%+21.5pp	-68.7%+19.1pp	-87.7%+68.3pp	-156.0%-6.1pp	-149.9%-36.6pp	-113.3%

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	-122.3%	N/A	-96.1%	N/A	-142.1%	N/A	-211.5%
Return on Equity	N/A	-29.2%	N/A	-12.5%	N/A	-12.5%	N/A	-10.8%
Return on Assets	N/A	-12.6%	N/A	-8.4%	N/A	-9.6%	N/A	N/A
Current Ratio	1.96-1.4	3.39-0.3	3.71-0.7	4.40+0.2	4.16-1.2	5.34-2.0	7.32	N/A
Debt-to-Equity	0.27+0.1	0.18+0.0	0.15+0.0	0.12+0.0	0.100.0	0.10+0.0	0.07	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Health Catalyst HCAT

$85.4M

Mobile-health Network Solutions MNDR

$3.0M

Lifemd Inc LFMD

$171.7M

Carecloud Inc CCLD

$153.8M

Simulations Plus Inc SLP

$241.0M

Frequently Asked Questions

What is Sophia Genetics Sa's annual revenue?

Sophia Genetics Sa (SOPH) reported $77.3M in total revenue for fiscal year 2025. This represents a 18.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Sophia Genetics Sa's revenue growing?

Sophia Genetics Sa (SOPH) revenue grew by 18.6% year-over-year, from $65.2M to $77.3M in fiscal year 2025.

Is Sophia Genetics Sa profitable?

No, Sophia Genetics Sa (SOPH) reported a net income of -$79.0M in fiscal year 2025, with a net profit margin of -102.2%.

How much debt does Sophia Genetics Sa have?

As of fiscal year 2025, Sophia Genetics Sa (SOPH) had $70.3M in cash and equivalents against $12.6M in long-term debt.

What is Sophia Genetics Sa's net profit margin?

Sophia Genetics Sa (SOPH) had a net profit margin of -102.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Sophia Genetics Sa's return on equity (ROE)?

Sophia Genetics Sa (SOPH) has a return on equity of -167.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Sophia Genetics Sa's free cash flow?

Sophia Genetics Sa (SOPH) generated -$36.5M in free cash flow during fiscal year 2025. This represents a 18.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Sophia Genetics Sa's operating cash flow?

Sophia Genetics Sa (SOPH) generated -$35.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Sophia Genetics Sa's total assets?

Sophia Genetics Sa (SOPH) had $163.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Sophia Genetics Sa's capital expenditures?

Sophia Genetics Sa (SOPH) invested $574K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Sophia Genetics Sa have outstanding?

Sophia Genetics Sa (SOPH) had 68M shares outstanding as of fiscal year 2025.

What is Sophia Genetics Sa's current ratio?

Sophia Genetics Sa (SOPH) had a current ratio of 1.96 as of fiscal year 2025, which is generally considered healthy.

What is Sophia Genetics Sa's debt-to-equity ratio?

Sophia Genetics Sa (SOPH) had a debt-to-equity ratio of 0.27 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Sophia Genetics Sa's return on assets (ROA)?

Sophia Genetics Sa (SOPH) had a return on assets of -48.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Sophia Genetics Sa's cash runway?

Based on fiscal year 2025 data, Sophia Genetics Sa (SOPH) had $70.3M in cash against an annual operating cash burn of $35.9M. This gives an estimated cash runway of approximately 23 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Sophia Genetics Sa's Piotroski F-Score?

Sophia Genetics Sa (SOPH) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Sophia Genetics Sa's earnings high quality?

Sophia Genetics Sa (SOPH) has an earnings quality ratio of 0.45x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Sophia Genetics Sa?

Sophia Genetics Sa (SOPH) scores 39 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.